<DOC>
	<DOCNO>NCT02303262</DOCNO>
	<brief_summary>The purpose study assess response rate ( per RECIST 1.1 ) participant receive mocetinostat gemcitabine document progression leiomyosarcoma gemcitabine contain regimen .</brief_summary>
	<brief_title>SARC018 : A Study Mocetinostat Gemcitabine Patients With Metastatic Leiomyosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Age ≥ 18 year Histologically document leiomyosarcoma Prior systemic therapy gemcitabine contain regimen ECOG Performance Status ≤ 1 Measurable metastatic disease target lesion increase size 20 % maximal dimension either within six month treatment chemotherapy use gemcitabine contain regimen Adequate organ function within 14 day study entry Patients legal representative must able read ( read ) , understand , sign write informed consent ( approved institutional review board ) within 14 day prior start treatment . Concurrent , clinically significant , active malignancy ( exclude basal cell carcinoma cervical intraepithelial neoplasia [ CIN ] situ melanoma situ ) ( Stage II portion ) Patients baseline QTcF ≥ 480 msec Patients uncontrolled concurrent illness , active infection require i.v . antibiotic , uncontrolled infection , fever &gt; 38.5°C day schedule dose Patients serious illness , medical condition , medical history , include prior history pericarditis/pericardial effusion , abnormal laboratory result , , investigator 's opinion , would likely interfere patient 's participation study , interpretation result Patients receive investigational drug within 28 day prior Day 1 study entry ( investigational drug one approve indication ) , receive concurrent treatment experimental drug anticancer therapy Pregnant lactate woman . Women childbearing potential ( WOCBP ) must negative serum pregnancy test document within 72 hour prior start study drug urine pregnancy test shall do Day 1 Cycle 1 Women child bear potential partner must use acceptable method contraception enrol study , period 3 month follow study drug treatment . Patients unwilling unable follow guideline exclude . Investigators follow Institutional standard regard acceptable method contraception . Known hypersensitivity HDAC inhibitor component mocetinostat Known hypersensitivity gemcitabine Any condition put patient undue risk discomfort result adherence study procedure . For example , consider requirement take mocetinostat water recommendation avoid agent increase gastric pH Any condition ( e.g. , know suspected poor compliance , psychological instability , geographical location , etc ) , judgment investigator , may affect patient 's ability sign inform consent undergo study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>